Tomohide Sugiyama

679 total citations
36 papers, 506 citations indexed

About

Tomohide Sugiyama is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Tomohide Sugiyama has authored 36 papers receiving a total of 506 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Tomohide Sugiyama's work include Lung Cancer Treatments and Mutations (23 papers), Lung Cancer Research Studies (21 papers) and Lung Cancer Diagnosis and Treatment (9 papers). Tomohide Sugiyama is often cited by papers focused on Lung Cancer Treatments and Mutations (23 papers), Lung Cancer Research Studies (21 papers) and Lung Cancer Diagnosis and Treatment (9 papers). Tomohide Sugiyama collaborates with scholars based in Japan and United States. Tomohide Sugiyama's co-authors include Takashi Hirose, Tohru Ohmori, Sojiro Kusumoto, Takao Shirai, Toshimitsu Yamaoka, Mitsuru Adachi, Kentaro Okuda, Tsukasa Ohnishi, Hiroo Ishida and Naoya Horichi and has published in prestigious journals such as Journal of Clinical Oncology, European Journal of Cancer and Psycho-Oncology.

In The Last Decade

Tomohide Sugiyama

36 papers receiving 496 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tomohide Sugiyama Japan	13	319	244	90	58	56	36	506
Kimito Yamada Japan	11	130 0.4×	334 1.4×	89 1.0×	26 0.4×	79 1.4×	40	583
Patrick Cobb United States	14	301 0.9×	105 0.4×	96 1.1×	18 0.3×	44 0.8×	43	476
Kun-Ming Rau Taiwan	14	335 1.1×	125 0.5×	194 2.2×	39 0.7×	78 1.4×	23	724
Mohammed Ibrahim Canada	13	281 0.9×	111 0.5×	43 0.5×	14 0.2×	46 0.8×	42	463
Takao Shirai Japan	13	302 0.9×	235 1.0×	115 1.3×	39 0.7×	64 1.1×	31	450
Silvia Graziani Brazil	11	152 0.5×	83 0.3×	148 1.6×	40 0.7×	132 2.4×	19	558
Antonio Di Meglio France	14	382 1.2×	209 0.9×	59 0.7×	15 0.3×	86 1.5×	67	571
Annie Yang United States	6	384 1.2×	109 0.4×	56 0.6×	42 0.7×	22 0.4×	14	559
Pearl H. Seo United States	12	256 0.8×	82 0.3×	161 1.8×	18 0.3×	116 2.1×	18	563
Cătălin Vlad Romania	12	175 0.5×	53 0.2×	108 1.2×	36 0.6×	68 1.2×	53	425

Countries citing papers authored by Tomohide Sugiyama

Since Specialization

Citations

This map shows the geographic impact of Tomohide Sugiyama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomohide Sugiyama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomohide Sugiyama more than expected).

Fields of papers citing papers by Tomohide Sugiyama

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomohide Sugiyama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomohide Sugiyama. The network helps show where Tomohide Sugiyama may publish in the future.

Co-authorship network of co-authors of Tomohide Sugiyama

This figure shows the co-authorship network connecting the top 25 collaborators of Tomohide Sugiyama. A scholar is included among the top collaborators of Tomohide Sugiyama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomohide Sugiyama. Tomohide Sugiyama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kasai, Takashi, Kiyoshi Mori, Tomohide Sugiyama, et al.. (2022). Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302. International Journal of Clinical Oncology. 27(12). 1841–1848. 2 indexed citations

Shukuya, Takehito, Ryo Ko, Yusuke Okuma, et al.. (2022). Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study. Cancers. 14(2). 331–331. 2 indexed citations

Yamaguchi, Ou, Hisao Imai, Hiroyuki Minemura, et al.. (2020). Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 85(4). 761–771. 39 indexed citations

Imai, Hisao, Ou Yamaguchi, Kensuke Suzuki, et al.. (2019). Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology. 146(2). 457–466. 22 indexed citations

Imai, Hisao, Yutaka Yamada, Hiroyuki Minemura, et al.. (2018). Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis. Thoracic Cancer. 9(12). 1699–1706. 5 indexed citations

Matsuguma, Haruhisa, Rie Nakahara, Tomohide Sugiyama, et al.. (2018). Definitive local therapy for oligo-recurrence in patients with completely resected non-small cell lung cancer.. Journal of Clinical Oncology. 36(15_suppl). 8527–8527. 3 indexed citations

Imai, Hisao, Tomohide Sugiyama, Tomohiro Tamura, et al.. (2017). A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients. Cancer Chemotherapy and Pharmacology. 80(3). 615–622. 12 indexed citations

Hirose, Takashi, Ken‐ichi Fujita, Sojiro Kusumoto, et al.. (2016). Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. Lung Cancer. 93. 69–76. 32 indexed citations

Okuma, Yusuke, Ryo Ko, Takehito Shukuya, et al.. (2016). Prognostic factors in patients with advanced thymic carcinoma treated with chemotherapy: A retrospective analysis of 289 patients from NEJ023 Study.. Journal of Clinical Oncology. 34(15_suppl). 8567–8567. 1 indexed citations

10.

Hirose, Takashi, Sojiro Kusumoto, Tomohide Sugiyama, et al.. (2014). Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer. Molecular and Clinical Oncology. 2(3). 405–410. 11 indexed citations

11.

Hirose, Takashi, Tomohide Sugiyama, Sojiro Kusumoto, et al.. (2012). Relationship of Circulating Tumor Cells to the Effectiveness of Cytotoxic Chemotherapy in Patients With Metastatic Non-Small-Cell Lung Cancer. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 20(2). 131–137. 55 indexed citations

12.

Kusumoto, Sojiro, Akihiko Tanaka, Tomohide Sugiyama, et al.. (2011). [A case of pulmonary aspergilloma concomitant with allergic bronchopulmonary aspergillosis].. PubMed. 49(5). 377–82. 2 indexed citations

13.

Hirose, Takashi, Toshimitsu Yamaoka, Sojiro Kusumoto, et al.. (2010). Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 67(4). 791–797. 6 indexed citations

14.

Hirose, Takashi, Kentaro Okuda, Toshimitsu Yamaoka, et al.. (2010). Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?. Lung Cancer. 71(2). 224–228. 30 indexed citations

15.

Kusumoto, Sojiro, Tomohide Sugiyama, Koichi Andō, et al.. (2009). Combination effect between bortezomib and tumor necrosis factor alpha on gefitinib-resistant non-small cell lung cancer cell lines.. PubMed. 29(6). 2315–22. 1 indexed citations

16.

Sugiyama, Tomohide, Takashi Hirose, Sojiro Kusumoto, et al.. (2007). Effectiveness of intensive follow-up after response in patients with small cell lung cancer. Lung Cancer. 59(2). 255–261. 17 indexed citations

17.

Andō, Koichi, Hiroo Ishida, Sojiro Kusumoto, et al.. (2007). Mutant epidermal growth factor receptor undergoes less protein degradation due to diminished binding to c-Cbl.. PubMed. 27(4B). 2253–63. 11 indexed citations

18.

Hirose, Takashi, Takao Shirai, Hiroo Ishida, et al.. (2007). Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 60(2). 267–274. 2 indexed citations

19.

Hirose, Takashi, Naoya Horichi, Tohru Ohmori, et al.. (2005). Patients Preferences in Chemotherapy for Advanced Non-small-cell Lung Cancer. Internal Medicine. 44(2). 107–113. 51 indexed citations

20.

Sugahara, Yoshiyuki, et al.. (1992). Clay-Organic Nano-Composite. Journal of the Ceramic Society of Japan. 100(1160). 413–416. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact